GoAI
Get started
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. logo

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

2196.HK

HKSEHealthcareDrug Manufacturers - Specialty & Generic

Open in GoAI

Latest quote

HK$16.80

−HK$0.57 · -3.28%

Aug 24, 3:59 PM HKT

2196.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a comprehensive healthcare enterprise, operating across Mainland China and international markets. Its principal activities include the research, development, production, and commercialization of pharmaceutical products. The company focuses on significant therapeutic domains such as oncology, immunology, metabolic disorders, gastrointestinal health, and central nervous system conditions. In addition to its drug offerings, Fosun Pharma provides medical devices and diagnostic solutions. Its multifaceted operations are organized into five key segments: pharmaceutical manufacturing, medical devices and diagnostics, healthcare services, pharmaceutical distribution and retail, and other business initiatives. This scope extends to managing healthcare facilities and hospitals, as well as the wholesale and retail distribution of medicines. The company was founded in 1994 and is headquartered in Shanghai, China.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Headquarters
CN
CEO
Yi Liu
Listed since
Oct 30, 2012
Employees
40,603

Market position

Volume
4.39M
1.45× average
Average volume
3.03M
Average daily volume
Market cap
62.93B HKD
Beta
0.44
Market reference 1

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
70.02B CNY
P/E (TTM)
17.27×
P/B (TTM)
1.22×
P/S (TTM)
1.42×
EV / EBITDA
11.36×
Earnings yield
7.07%
Free cash flow yield
1.65%
Dividend yield
1.71%

Profitability & efficiency

Gross margin
49.44%
Operating margin
9.63%
Net margin
8.22%
Return on equity
6.74%
Return on assets
2.73%
Return on invested capital
2.00%

Financial health

Debt / equity
0.81×
Current ratio
0.93×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends54%37%19%1%Gross margin, FY2021: 48.14%Gross margin, FY2022: 47.28%Gross margin, FY2023: 47.54%Gross margin, FY2024: 47.97%Gross margin, FY2025: 49.88%Operating margin, FY2021: 16.19%Operating margin, FY2022: 18.88%Operating margin, FY2023: 7.99%Operating margin, FY2024: 10.34%Operating margin, FY2025: 6.27%Net margin, FY2021: 12.12%Net margin, FY2022: 8.49%Net margin, FY2023: 5.76%Net margin, FY2024: 6.74%Net margin, FY2025: 8.12%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 48.14%. Gross margin FY2022 47.28%. Gross margin FY2023 47.54%. Gross margin FY2024 47.97%. Gross margin FY2025 49.88%. Operating margin FY2021 16.19%. Operating margin FY2022 18.88%. Operating margin FY2023 7.99%. Operating margin FY2024 10.34%. Operating margin FY2025 6.27%. Net margin FY2021 12.12%. Net margin FY2022 8.49%. Net margin FY2023 5.76%. Net margin FY2024 6.74%. Net margin FY2025 8.12%.

Income trends

Revenue

40.42B CNY-1.57%

Operating income

2.54B CNY-40.28%

Net income

3.28B CNY+18.54%
Income trends across reported periods48.11B CNY31.48B CNY14.86B CNY−1.77B CNYRevenue, FY2021: 39.01B CNYRevenue, FY2022: 43.95B CNYRevenue, FY2023: 41.4B CNYRevenue, FY2024: 41.07B CNYRevenue, FY2025: 40.42B CNYOperating income, FY2021: 6.31B CNYOperating income, FY2022: 8.3B CNYOperating income, FY2023: 3.31B CNYOperating income, FY2024: 4.25B CNYOperating income, FY2025: 2.54B CNYNet income, FY2021: 4.73B CNYNet income, FY2022: 3.73B CNYNet income, FY2023: 2.39B CNYNet income, FY2024: 2.77B CNYNet income, FY2025: 3.28B CNYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 39.01B CNY. Revenue FY2022 43.95B CNY. Revenue FY2023 41.4B CNY. Revenue FY2024 41.07B CNY. Revenue FY2025 40.42B CNY. Operating income FY2021 6.31B CNY. Operating income FY2022 8.3B CNY. Operating income FY2023 3.31B CNY. Operating income FY2024 4.25B CNY. Operating income FY2025 2.54B CNY. Net income FY2021 4.73B CNY. Net income FY2022 3.73B CNY. Net income FY2023 2.39B CNY. Net income FY2024 2.77B CNY. Net income FY2025 3.28B CNY.
Metric (CNY)FY2025FY2024FY2023FY2022FY2021
Revenue40.42B CNY41.07B CNY41.4B CNY43.95B CNY39.01B CNY
Cost of goods sold20.26B CNY21.37B CNY21.72B CNY23.17B CNY20.23B CNY
Gross profit20.16B CNY19.7B CNY19.68B CNY20.78B CNY18.78B CNY
Research and development3.91B CNY3.64B CNY4.37B CNY4.3B CNY3.83B CNY
Selling, general, and administrative6.8B CNY6.47B CNY14.2B CNY10.16B CNY9.95B CNY
Operating expenses17.63B CNY15.46B CNY16.5B CNY17.15B CNY16.06B CNY
Interest income292.73M CNY404.64M CNY327.48M CNY282.63M CNY233.73M CNY
Interest expense1.23B CNY1.55B CNY1.32B CNY963.81M CNY822.53M CNY
Depreciation and amortization3.63B CNY3B CNY2.97B CNY2.34B CNY1.83B CNY
Operating income2.54B CNY4.25B CNY3.31B CNY8.3B CNY6.31B CNY
Net income3.28B CNY2.77B CNY2.39B CNY3.73B CNY4.73B CNY

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
55%
6 beats, 5 misses, 0 met estimates
Average EPS surprise
+22.33%
11 comparable reports
Latest EPS result
0.38
Estimate 0.35 · Beat by 5.92%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.740.570.40.23Q4 '24MissQ1 '25MissQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26Estimate
Q4 2024, reported Oct 29, 2024: actual 0.29, estimate 0.3, surprise -3.33%, Miss. Q1 2025, reported Mar 25, 2025: actual 0.298, estimate 0.3, surprise -0.70%, Miss. Q2 2025, reported Apr 29, 2025: actual 0.31, estimate 0.296, surprise +4.60%, Beat. Q3 2025, reported Aug 26, 2025: actual 0.701, estimate 0.275, surprise +155.19%, Beat. Q4 2025, reported Oct 29, 2025: actual 0.339, estimate 0.3, surprise +12.93%, Beat. Q1 2026, reported Mar 24, 2026: actual 0.69, estimate 0.29, surprise +138.10%, Beat. Q2 2026, reported Apr 27, 2026: actual 0.376, estimate 0.355, surprise +5.92%, Beat. Q3 2026, reported Aug 25, 2026: actual —, estimate 0.355, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates25.27B19.82B14.37B8.93BQ4 '24MissQ1 '25MissQ2 '25MissQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26Estimate
Q4 2024, reported Oct 29, 2024: actual 11.56B HKD, estimate 12.81B HKD, surprise -9.76%, Miss. Q1 2025, reported Mar 25, 2025: actual 10.8B HKD, estimate 11.01B HKD, surprise -1.92%, Miss. Q2 2025, reported Apr 29, 2025: actual 10.05B HKD, estimate 10.46B HKD, surprise -3.87%, Miss. Q3 2025, reported Aug 26, 2025: actual 21.29B HKD, estimate 10.83B HKD, surprise +96.55%, Beat. Q4 2025, reported Oct 29, 2025: actual 10.8B HKD, estimate 10.16B HKD, surprise +6.24%, Beat. Q1 2026, reported Mar 24, 2026: actual 24.15B HKD, estimate 12.61B HKD, surprise +91.46%, Beat. Q2 2026, reported Apr 27, 2026: actual 11.47B HKD, estimate 11.12B HKD, surprise +3.12%, Beat. Q3 2026, reported Aug 25, 2026: actual —, estimate 12.97B HKD, surprise —, Comparison unavailable.

Corporate actions

Annual dividends per share

Cash distributions grouped by calendar year; partial years are marked.

HK$0.35

2025 complete year-32.7% since 2021

2026 partial: HK$0.45

* Partial calendar year in the available dividend history.

Corporate action history

Dividend

Ex-dividend Jul 16, 2026

HK$0.45

Annual

Record Jul 17, 2026 · Payment Aug 14, 2026

Dividend

Ex-dividend Jul 24, 2025

HK$0.35

Annual

Record Jul 25, 2025 · Payment Aug 22, 2025

Dividend

Ex-dividend Jul 26, 2024

HK$0.30

Annual

Record Jul 29, 2024 · Payment Aug 23, 2024

Dividend

Ex-dividend Jul 31, 2023

HK$0.46

Annual

Record Aug 1, 2023 · Payment Aug 24, 2023

Dividend

Ex-dividend Jun 8, 2022

HK$0.66

Annual

Record Jun 9, 2022 · Payment Jul 4, 2022

Dividend

Ex-dividend Jul 7, 2021

HK$0.52

Annual

Record Jul 8, 2021 · Payment Aug 3, 2021

2196.HK peers

WuXi AppTec Co., Ltd. logo

2359.HK

WuXi AppTec Co., Ltd.

HK$197.4

-4.08%

Jiangsu Hengrui Pharmaceuticals Co.,Ltd logo

1276.HK

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

HK$46.66

-3.20%

BeOne Medicines AG logo

6160.HK

BeOne Medicines AG

HK$221.4

-2.89%

WuXi Biologics (Cayman) Inc. logo

2269.HK

WuXi Biologics (Cayman) Inc.

HK$48.42

-5.06%

Hansoh Pharmaceutical Group Company Limited logo

3692.HK

Hansoh Pharmaceutical Group Company Limited

HK$31.10

-5.99%

Innovent Biologics, Inc. logo

1801.HK

Innovent Biologics, Inc.

HK$99.45

-2.88%

ETFs holding 2196.HK

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard FTSE Emerging Markets ETF logoVanguard FTSE Emerging Markets ETFVWO
Market value
14.52M
Weight
0.01%
AUM
162.3B USD
Expense ratio
0.06%
Price / 1D
$60.45+0.72%
Vanguard Total International Stock ETF logoVanguard Total International Stock ETFVXUS
Market value
13.86M
Weight
0.00%
AUM
646.2B USD
Expense ratio
0.05%
Price / 1D
$87.71+0.78%
Vanguard FTSE All-World ex-US ETF logoVanguard FTSE All-World ex-US ETFVEU
Market value
3.21M
Weight
0.00%
AUM
95.9B USD
Expense ratio
0.04%
Price / 1D
$85.69+0.82%
Vanguard International High Dividend Yield ETF logoVanguard International High Dividend Yield ETFVYMI
Market value
1.29M
Weight
0.01%
AUM
21.9B USD
Expense ratio
0.07%
Price / 1D
$105.25+1.02%
Schwab Emerging Markets Equity ETF logoSchwab Emerging Markets Equity ETFSCHE
Market value
1.16M
Weight
0.01%
AUM
12.89B USD
Expense ratio
0.06%
Price / 1D
$36.97+0.71%
Dimensional - Emerging Markets Core Equity 2 ETF logoDimensional - Emerging Markets Core Equity 2 ETFDFEM
Market value
1.16M
Weight
0.01%
AUM
9.49B USD
Expense ratio
0.39%
Price / 1D
$39.93+0.50%
Vanguard Total World Stock ETF logoVanguard Total World Stock ETFVT
Market value
774.27K
Weight
0.00%
AUM
97.9B USD
Expense ratio
0.06%
Price / 1D
$160.77+0.53%
WisdomTree China ex-State-Owned Enterprises Fund logoWisdomTree China ex-State-Owned Enterprises FundCXSE
Market value
552.69K
Weight
0.10%
AUM
498.55M USD
Expense ratio
0.32%
Price / 1D
$38.6037+0.56%

Continue in GoAI

Research 2196.HK

research.disclaimer